| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 02/14/2002 | WO2001049274A3 Methods for pulmonary delivery of interleukin-2 |
| 02/14/2002 | WO2001045725A3 Treatment for inflammatory bowel disease (ibd) and related conditions |
| 02/14/2002 | WO2001044489A3 Galactomannan oligosaccharides and methods for the production and use thereof |
| 02/14/2002 | WO2001042288A3 G-protein coupled receptors |
| 02/14/2002 | WO2001041742A3 Antiviral medication |
| 02/14/2002 | WO2001038362A3 Production of vaccines |
| 02/14/2002 | WO2001034641A3 Antimicrobial activity of the first cationic cluster of human lactoferrin |
| 02/14/2002 | WO2000068258A3 Compounds exhibiting an antibiotic activity |
| 02/14/2002 | WO2000067698A3 Method for controlling the fidelity and execution of reverse transcriptase by incorporating and polymerising nucleotide analogues acceptable as substrates without blocking its elongation |
| 02/14/2002 | WO2000059469A9 Endodontic fibers and methods of use therefor |
| 02/14/2002 | US20020019563 A S-(2-(1-iminoethyl)amino)ethyl)-2-methyl-L-cysteine |
| 02/14/2002 | US20020019534 Gem substituted hydroxamic acids |
| 02/14/2002 | US20020019530 Antitumor agent |
| 02/14/2002 | US20020019515 Novel spoIIIE |
| 02/14/2002 | US20020019437 Aids therapy |
| 02/14/2002 | US20020019424 1-sulfonyl pyrrolidine derivatives |
| 02/14/2002 | US20020019423 Anti-viral triaza compounds |
| 02/14/2002 | US20020019413 4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxamides as antiviral agents |
| 02/14/2002 | US20020019411 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| 02/14/2002 | US20020019404 Anticancer agents, skin disorders |
| 02/14/2002 | US20020019397 Heterocycle carboxamides as antiviral agents |
| 02/14/2002 | US20020019393 Treating inflammation, autoimmune diseases, destructive bone disorders, proliferative disorders, infections, neurvous system disorders, reperfusion/ischemia in stroke, cardiovascular disorders, hypoxia, edema, fever, pain |
| 02/14/2002 | US20020019381 In fewer steps and is obtained in higher yield; chemical intermediates; useful in treating methicillin resistent Staphylococcus aureus and Pseudomonas aeruginosa |
| 02/14/2002 | US20020019376 Steroid derived antibiotics |
| 02/14/2002 | US20020019365 Encapsulation is dissolution resistant at a pH of about 4 to 5 or less and dissolves at a pH of greater than about 4 to 5 |
| 02/14/2002 | US20020019363 Viricides for hepatitis c |
| 02/14/2002 | US20020019353 Single-dose administration |
| 02/14/2002 | US20020019341 Modulation of systemic memory T cell trafficking |
| 02/14/2002 | US20020019041 Storing adenoviruses; preparing liquid composition, maintain liquid at freezing, monitor adenovirues for activity |
| 02/14/2002 | US20020018814 Chlorhexidine formulations, new chlorhexidine salts, solutions containing these and their use |
| 02/14/2002 | US20020018812 Sponge-like or foam |
| 02/14/2002 | US20020018787 Synergistic mixture of dimethylglycine and mussel extract |
| 02/14/2002 | US20020018784 Vaccine against mumps containing a jeryl-lynn virus strain |
| 02/14/2002 | US20020018782 Binding to antibodies; prophylaxis, therapy of infections |
| 02/14/2002 | US20020018780 Administering protein, polypeptide containing neutralizing antibodies |
| 02/14/2002 | US20020018770 Method for administering viable microorganism composition for poultry |
| 02/14/2002 | DE10038571A1 Zusammensetzungen und Dosierungsformen zur Anwendung in der Mundhöhle bei der Bhandlung von Mykosen Compositions and dosage forms for use in the oral cavity in Bhandlung mycoses |
| 02/14/2002 | DE10038022A1 Inverse Thiazolylamid-Derivate Inverse Thiazolylamid derivatives |
| 02/14/2002 | DE10036871A1 Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe Dispersions for the formulation of poorly soluble drugs or little |
| 02/14/2002 | DE10035991A1 Nagellackzusammensetzung Nail polish composition |
| 02/14/2002 | DE10031043A1 Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung Delayed-release preparations of quinolone antibiotics and methods for their preparation |
| 02/14/2002 | CA2775616A1 Salts of benzimidazole compound and application thereof |
| 02/14/2002 | CA2774959A1 Method of using diketopiperazines and composition containing them |
| 02/14/2002 | CA2432423A1 Stabilization of immunogens derived from paramyxoviruses |
| 02/14/2002 | CA2423519A1 A new slit-like protein obtained from a cdna library from hs-5 stromal cell line |
| 02/14/2002 | CA2419044A1 Macrolide antibiotics |
| 02/14/2002 | CA2418912A1 Neuroprotective 2-pyridinamine compositions and related methods |
| 02/14/2002 | CA2418445A1 Stress proteins and peptides and methods of use thereof |
| 02/14/2002 | CA2418091A1 Virus-like particles and process for producing the same |
| 02/14/2002 | CA2418083A1 Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists |
| 02/14/2002 | CA2418023A1 Combinations of dalfopristine/quinupristine with cefpirome |
| 02/14/2002 | CA2417967A1 Azabicyclic derivatives and their therapeutic use |
| 02/14/2002 | CA2417930A1 Pharmaceutical compositions containing lithium carbonate |
| 02/14/2002 | CA2417767A1 Peptides presented by cells |
| 02/14/2002 | CA2417755A1 Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| 02/14/2002 | CA2417707A1 Sid.rtm. nucleic acids and polypeptides selected from a pathogenic strain of hepatitis c virus and applications thereof |
| 02/14/2002 | CA2417604A1 Use of essential oils for combating gi tract infection by helicobacter-like organisms |
| 02/14/2002 | CA2417587A1 Transporters and ion channels |
| 02/14/2002 | CA2417098A1 The use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands |
| 02/14/2002 | CA2416982A1 Lactobacillus rhamnosus polynucleotides, polypeptides and methods for using them |
| 02/14/2002 | CA2412368A1 Benzimidazole derivatives, preparation and therapeutic use thereof |
| 02/14/2002 | CA2411928A1 Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclindependent kinases |
| 02/14/2002 | CA2386725A1 Novel pharmaceutical compositions of anti-tubercular drugs and process for their preparation |
| 02/14/2002 | CA2386103A1 Vascular endothelial growth factor 2 |
| 02/13/2002 | EP1179533A2 Salt of naphthyridine carboxylic acid derivative |
| 02/13/2002 | EP1179349A1 W/O emulsion adjuvant compositions for vaccines |
| 02/13/2002 | EP1179090A1 Nucleic acid probe-based diagnostic assays for prokaryotic and eukaryotic organisms |
| 02/13/2002 | EP1179082A2 Improved retroviral production by inhibition of the enveloppe cell receptor |
| 02/13/2002 | EP1179072A2 Combination neisserial compositions |
| 02/13/2002 | EP1179067A1 Neuroprotective properties of gdf-15, a novel member of the tgf-beta superfamily |
| 02/13/2002 | EP1179066A2 Extracellular signaling molecules |
| 02/13/2002 | EP1179065A2 Full-length molecules expressed in human tissues |
| 02/13/2002 | EP1179064A2 Secreted polypeptides and corresponding polynucleotides |
| 02/13/2002 | EP1179022A2 Bufornin 1 as a specific inhibitor and therapeutic agent for botulinum toxin b and tetanus neurotoxins |
| 02/13/2002 | EP1179012A1 Long lasting fusion peptide inhibitors or viral infection |
| 02/13/2002 | EP1179010A2 Previns as specific inhibitors and therapeutic agents for botulinum toxin b and tetanus neurotoxins |
| 02/13/2002 | EP1179007A1 Self-assembling biomolecular structures |
| 02/13/2002 | EP1179002A1 Methods using mechanisms of action of aroa |
| 02/13/2002 | EP1178999A2 L-ribo-lna analogues |
| 02/13/2002 | EP1178993A1 Thiazoloderiatives and pharmaceutical compositions containing them |
| 02/13/2002 | EP1178984A2 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives |
| 02/13/2002 | EP1178983A1 Indole-type derivatives as inhibitors of p38 kinase |
| 02/13/2002 | EP1178981A1 Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods |
| 02/13/2002 | EP1178977A1 Ion channel modulating agents |
| 02/13/2002 | EP1178963A1 Ion channel modulating agents |
| 02/13/2002 | EP1178954A1 A structure-based approach to design inhibitors of protein-processivity factor interactions |
| 02/13/2002 | EP1178952A1 NOVEL INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR-$g(a) MODULATORS, SYNTHESES OF SAID MODULATORS AND METHODS OF USING SAID MODULATORS |
| 02/13/2002 | EP1178903A1 Drive system |
| 02/13/2002 | EP1178829A1 Human monoclonal antibody |
| 02/13/2002 | EP1178828A1 Death domain containing receptor 4 |
| 02/13/2002 | EP1178827A1 Use of antibodies identifying the interleukin-2 receptor for preventing and/or treating hiv infections |
| 02/13/2002 | EP1178825A2 Adjuvant combination formulations |
| 02/13/2002 | EP1178824A2 Staphylococcus aureus antigen-containing whole cell vaccine |
| 02/13/2002 | EP1178820A1 Methods of modulating fabh activity |
| 02/13/2002 | EP1178819A2 Glutathione reductase for therapy and prophylaxis of aids |
| 02/13/2002 | EP1178797A1 Inhibitors of impdh enzyme |
| 02/13/2002 | EP1178785A1 Compositions and methods for identifying antigens which elicit an immune response |
| 02/13/2002 | EP1178781A1 Multilayer pharmaceutical product for release in the colon |
| 02/13/2002 | EP1178736A1 A composition containing carvacrol and thymol for use as a bactericide |
| 02/13/2002 | EP1178729A1 Microbially resistant compositions |